



Press Release

Change in the Advisory Board of MiP Pharma Group

As of today, July 31, 2025, Dr. Axel Müller, our long-standing Chairman of the Advisory Board of the MiP Group, is stepping down from his advisory mandate at his own request.

In his personal statement, he described the recent sale of the Homburg facility as a significant milestone in the ongoing development of MiP and, consequently, as the right moment to conclude his mandate as Chairman of its Advisory Board in order to gain more freedom for his personal life planning.

The shareholders, advisory board, and management regret this decision and extend their sincere thanks to Dr. Axel Müller for his many years of trusted collaboration, his outstanding commitment to MiP's interests, and his valuable contributions to its successful development.

Dr. Axel Müller has agreed to remain available to MiP Pharma as a Senior Advisor and, in this role, will also continue to participate in representing MiP Pharma in the committees of the industry association Pro Generika.

About MiP Pharma Group

The MiP Pharma Group markets prescription generics, primarily antibiotics, over-the-counter medicines and medical devices. The main markets are Germany and Poland as well as some other Eastern European markets. The sales focus is on the hospital business and addressing selected specialist groups. With over 200 employees and around 400 marketing authorisations, MiP Pharma generated sales of around 50 million euros in the last financial year. Since November 2020, the previously family-run MiP Pharma has been a portfolio company of the Berlin-based financial investor capiton AG.

Media Contact

Evelyn Back

0176 63613964

buero@evelynback.com